(August 24, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) , declared that the Clinical Trial (identifier: NCT04446429) to conduct research for Proxalutamide (GT0918) as a treatment for the coronavirus disease (“COVID-19”)has recorded the first patient enrolment in Brazil. The Company plans to enrol a total of 381 subjects and it’s expected that the enrolment will be completed in 2 months.

As a new generation androgen receptor (AR) antagonist, Proxalutamide is a potential best-in-class innovative drug for prostate cancer. It is undergoing a multiple of phase I-III clinical trials in China and the United States for mCRPC as well as metastatic breast cancer. As COVID-19 is raging in the world, to address the urgent clinical demand, based on pre-clinical research result of Kintor Pharmaceutical and the research data of the clinical review of Applied Biology, both parties agree to carry out a clinical study on the treatment of COVID-19. The Clinical Trial is a prospective, interventional, placebo controlled, double-blinded, randomised parallel assignment study exploring the anti-androgen treatment for COVID-19.

Dr. Youzhi TONG, founder, Chairman and Chief Executive Officer of Kintor Pharmaceutical, said: “we reached clinical cooperation agreement with Applied Biology on July 13 and completed works including optimization of clinical protocol, seeking approval from Brazil’s drug regulators and hospitals and drug transportation in only 37 days. Under the concerted efforts of both parties, we finally realized the enrolment of first subject today. I want to give special thanks to all team members. This is the social responsibility that we shall actively take to address the raging pandemic throughout the world including Brazil. I also hope we can find solutions for the treatment of COVID-19, especially for slowing down the progression of illness.